<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0000835"><a href="http://purl.obolibrary.org/obo/MONDO_0000835">MONDO:0000835</a></h3>
<p><strong>Label:</strong> ischemic bone disease</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0016320">MONDO:0016320</a> (rare hereditary thrombophilia), <a href="http://purl.obolibrary.org/obo/MONDO_0018379">MONDO:0018379</a> (primary avascular necrosis), <a href="http://purl.obolibrary.org/obo/MONDO_0018377">MONDO:0018377</a> (rare hereditary disease with avascular necrosis), <a href="http://purl.obolibrary.org/obo/MONDO_0018374">MONDO:0018374</a> (secondary avascular necrosis), <a href="http://purl.obolibrary.org/obo/MONDO_0019144">MONDO:0019144</a> (hereditary thrombophilia due to congenital protein S deficiency), <a href="http://purl.obolibrary.org/obo/MONDO_0019145">MONDO:0019145</a> (hereditary thrombophilia due to congenital protein c deficiency), <a href="http://purl.obolibrary.org/obo/MONDO_0018373">MONDO:0018373</a> (avascular necrosis), <a href="http://purl.obolibrary.org/obo/MONDO_0018381">MONDO:0018381</a> (osteochondrosis), <a href="http://purl.obolibrary.org/obo/MONDO_0005380">MONDO:0005380</a> (osteonecrosis),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_399185">Orphanet:399185</a>, <a href="http://www.orpha.net/ORDO/Orphanet_399164">Orphanet:399164</a>, <a href="http://www.orpha.net/ORDO/Orphanet_399158">Orphanet:399158</a>, <a href="http://www.orpha.net/ORDO/Orphanet_217454">Orphanet:217454</a>, <a href="http://www.orpha.net/ORDO/Orphanet_399169">Orphanet:399169</a>, <a href="http://purl.obolibrary.org/obo/OMIM_614514">OMIM:614514</a>, <a href="http://purl.obolibrary.org/obo/OMIM_176860">OMIM:176860</a>, <a href="http://www.orpha.net/ORDO/Orphanet_399302">Orphanet:399302</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612336">OMIM:612336</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612304">OMIM:612304</a>, <a href="http://www.orpha.net/ORDO/Orphanet_745">Orphanet:745</a>, <a href="http://www.orpha.net/ORDO/Orphanet_399319">Orphanet:399319</a>, <a href="http://www.orpha.net/ORDO/Orphanet_743">Orphanet:743</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0004418">HP:0004418</a> (Thrombophlebitis) and (not (<a href="http://purl.obolibrary.org/obo/HP_0004419">HP:0004419</a> (Recurrent thrombophlebitis))) 69.23%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0004418">HP:0004418</a> (Thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0100724">HP:0100724</a> (Hypercoagulability) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0004418">HP:0004418</a> (Thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0030780">HP:0030780</a> (Abnormality of the protein C anticoagulant pathway) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0004418">HP:0004418</a> (Thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0011354">HP:0011354</a> (Generalized abnormality of skin) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0004418">HP:0004418</a> (Thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0011121">HP:0011121</a> (Abnormality of skin morphology) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003256">HP:0003256</a> (Abnormality of the coagulation cascade) and <a href="http://purl.obolibrary.org/obo/HP_0004418">HP:0004418</a> (Thrombophlebitis) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0100724">HP:0100724</a> (Hypercoagulability) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0030875">HP:0030875</a> (Abnormality of pulmonary circulation) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0030780">HP:0030780</a> (Abnormality of the protein C anticoagulant pathway) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0030163">HP:0030163</a> (Abnormal vascular physiology) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0011025">HP:0011025</a> (Abnormality of cardiovascular system physiology) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0003256">HP:0003256</a> (Abnormality of the coagulation cascade) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) and <a href="http://purl.obolibrary.org/obo/HP_0002795">HP:0002795</a> (Functional respiratory abnormality) 65.38%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002597">HP:0002597</a> (Abnormality of the vasculature) and <a href="http://purl.obolibrary.org/obo/HP_0002638">HP:0002638</a> (Superficial thrombophlebitis) 65.38%</li>
</ul>
</body>
</html>
